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Abstract  
 
In-frame exon deletions of the DMD gene produce internally truncated proteins that typically 
lead to Becker muscular dystrophy (BMD), a milder allelic disorder of Duchenne muscular 
dystrophy (DMD). We hypothesized that differences in the structure of mutant dystrophin 
may be responsible for the clinical heterogeneity observed in Becker patients and we studied 
four prevalent in-frame exon deletions, i.e. ∆45-47, ∆45-48, ∆45-49 and ∆45-51. Molecular 
homology modelling revealed that the proteins corresponding to deletions ∆45-48 and ∆45-51 
displayed a similar structure (hybrid repeat) than the wild type dystrophin, whereas deletions 
∆45-47 and ∆45-49 lead to proteins with an unrelated structure (fractional repeat). All four 
proteins in vitro expressed in a fragment encoding repeats 16 to 21 were folded in alpha-
helices and remained highly stable. Refolding dynamics were slowed and molecular surface 
hydrophobicity were higher in fractional repeat containing ∆45-47 and ∆45-49 deletions 
compared to hybrid repeat containing ∆45-48 and ∆45-51 deletions. By retrospectively 
collecting data for a series of French BMD patients, we showed that the age of dilated 
cardiomyopathy onset was delayed by 11 and 14 years in ∆45-48 and ∆45-49 compared to 
∆45-47 patients, respectively. A clear trend toward earlier wheelchair dependency (minimum 
of 11 years) was also observed in ∆45-47 and ∆45-49 patients compared to ∆45-48 patients. 
Muscle dystrophin levels were moderately reduced in most patients without clear correlation 
with the deletion type. Disease progression in BMD patients appears to be dependent on the 
deletion itself and associated with a specific structure of dystrophin at the deletion site.  
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Introduction  
The DMD gene is the largest human gene (79 exons and 2.4 Mb). It encodes the protein 
dystrophin and is subject to a high number of mutations, with the majority (approximately 
70%) being deletions of one or several exons (1). A complete loss of dystrophin due to out-of-
frame mutations leads to Duchenne muscular dystrophy (DMD), a severe and rapidly 
progressive muscular disease, characterised by early onset and wheelchair (WC) dependency 
before the age of 13 years (2). In about 1 to 10 for 100,000 male individuals (3-5), the 
deletions do not disrupt the reading frame, and an internally truncated dystrophin is produced, 
leading predominantly to Becker muscular dystrophy (BMD), an allelic disorder milder than 
DMD. BMD is clinically heterogeneous with some affected individuals being able to 
experience a near normal lifestyle and lifespan, while others lose the ability to walk in their 
late teens or early twenties (6-9). Cardiac involvement is a prominent feature of the disease, 
and heart failure is the most common cause of early death in BMD patients (10-13).   
Dystrophin is a large filamentous protein of 3,685 residues and a molecular weight of 427 k 
Da (14) that protects the sarcolemma from the mechanical stresses of muscle contraction. It 
belongs to the cytoskeletal family of proteins able to assemble into macromolecular structures 
with high numbers of protein and lipid partners (15). Dystrophin is composed of four 
domains: (a) an N-terminal actin-binding domain (ABD1) (approximately exons 1-8); (b) a 
central rod-like domain composed of 24 spectrin-like repeats folded in a triple alpha-helical 
coiled-coil and connected to the flanking domains by hinges (approximately exons 10-60); (c) 
a Cys-rich domain, which links the cytoskeleton to the extracellular matrix via the membrane 
with a dystrophin-associated glycoprotein complex (approximately exons 61-69); and (d) the 
C-terminal end (approximately exons 70-79). We recently characterised the central rod 
domain using a computational approach and showed that it is organised in separate and 
putatively specialised functional regions (16).   
The central rod domain accounts for more than 76% of the protein and is the site of the great 
majority of the deletions that cause BMD (17, 18), specifically deletions encompassing exons 
44 to 51 that encode repeats 17 to 20 (R17-20). Although located in the same gene region, 
these in-frame deletions are associated with variable clinical severity in BMD patients. It had 
already been suggested that the cause of this clinical variability could be attributable to 
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structural modifications of dystrophin (12, 19, 20). However, this hypothesis has never been 
thoroughly tested.  
In this study, we intended to clarify the role of dystrophin structure in the clinical 
heterogeneity of the BMD patients carrying different in-frame deletions in the mutational hot 
spot of the DMD gene, i.e., deletions of exons 45-47, 45-48, 45-49 and 45-51. We modeled 
the molecular structures and analyzed the biochemical characteristics of the corresponding 
dystrophins after introducing the deletions into a fragment that includes the repeats 16 to 21 
(R16-21). Concomitantly, we retrospectively collected data measuring cardiac and motor 
function in a large cohort of French BMD patients bearing these four deletions. A semi-
quantitative assessment of dystrophin levels was also collected in about half of the patients. 
The analysis of clinical, modeling and biochemical data provide clear evidence that the 
structural characteristics of dystrophin at the deletion site are strongly associated with 
phenotype severity in BMD patients. Notably, ∆45-48 and ∆45-51 deletions, which exhibit 
structural features similar to wild type protein at the deletion site, are associated with a slower 
disease progression compared to ∆45-47 or ∆45-49 deletions which both lead to profound 
structural modifications of dystrophin. 
 
Results  
 
Molecular modelling of the internally truncated proteins shows hybrid vs. 
fractional repeats at the deletion site of dystrophin 
All models (Fig. 1) were assessed using PROCHECK (21), which calculated the values of the 
Φ / Ψ dihedral angles of the peptide bond for each residue (i.e. the Ramachandran plot) within 
the atomic models. Most of the residues of the initial models were in the most energetically 
favoured regions while less than 2% of residues were in energetically unfavoured regions 
(Table 1). These last residues were situated in loops regions that are highly dynamic and thus 
with a structuration more difficult to predict by homology modelling. Overall, these data 
showed that the models were of high quality. As shown by molecular homology modelling 
(16) and crystallography (22), each dystrophin repeat is composed of three helices, A, B and 
C, which form a triple helical coiled-coil (Fig. 1, inset). The four truncated dystrophin 
exhibited modified structures compared to the wild type R16-21. They all bear deletions 
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starting at exon 45, which encodes the C-terminal half of repeat 17 that is therefore lacking in 
all studied deletion mutants. However, two types of structures were observed at the deletion 
site, namely hybrid or fractional repeats (18). Hybrid repeats with structure similar to triple 
coiled-coil repeat structure at the deletion site were observed in R∆45-48 and R∆45-51 (with 
and without hinge 3, respectively). Fractional repeats that do not reconstitute a native triple 
coiled-coil repeat at the deletion site were observed in R∆45-47 and R∆45-49 (both with 
hinge 3).  
To assess the stability of these models, molecular dynamics (MD) relaxation was performed. 
The Root Mean Square Deviation (RMSD: see Material and Methods section for definition) 
of the Cα atoms was measured and showed that the models reached equilibrium for the last 22 
ns of the MD trajectory (Fig. 1S). The repeats globally maintained their tri-dimensional 
structures as showed by their Φ / Ψ dihedral angles with an increase of residues situated in the 
energetically favoured regions of the Ramachandran plots (Table 1). The number of residues 
in energetically unfavoured regions decreased substantially after the MD relaxation indicating 
an increase of the global quality of the models. The analysis of the fluctuations by the Root 
Mean Square of Fluctuation (RMSF: see Material and Methods section for definition) (Fig. 
2S) of each Cα atom along the sequence showed that all the models maintained their 
secondary structures, helices and loops. By analysing the conformational clustering (Fig. 3S), 
it was evident that the models presented specific points of flexibility shown by arrows in Fig. 
2A.  A flexibility spot was located for the R16-21 wild type model at the junction between the 
repeats 18 and 19. Remarkably, the flexibility of the two fractional repeats was enhanced at 
the deletion sites themselves, indicating that these sites represent points of structural 
weakness. This contrasted with the two deleted proteins exhibiting hybrid repeats, as the 
R∆45-48 structure showed flexibility at the hinge 3 region, while R∆45-51 exhibited a 
remarkably stable structure (no arrow).  
 
Molecular descriptors of the truncated dystrophins compared to wild type 
The electrostatic potential and molecular hydrophobicity potential profiles of the truncated 
dystrophins were profoundly modified compared to wild type dystrophin. The electrostatic 
potential at the C-terminal region of the new junction site differed dramatically from one 
protein to another (Fig. 2B), without specific variations corresponding to hybrid or fractional 
repeats. The sequence predicted isoelectric point pI increased from 5.38 for the wild type to 
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6.32 for the R∆45-51 (Fig. 2C) showing that an identical N-terminal region was joined to a C-
terminal region with increasing cationic properties as the deletion size increased. By contrast, 
the variations in the molecular hydrophobicity potential were related with the hybrid or 
fractional structure type at the deletion site (Fig 2D, E). Clearly, a higher hydrophobic surface 
was exposed to the solvent in fractional repeats compared to hybrid repeats. In the fractional 
repeat-containing proteins, whether composed by small helices (R∆45-47) or by a double 
coiled-coil (R∆45-49), hydrophobic residues normally buried in the wild type repeats were 
largely exposed to the surface. For the hybrid repeat-containing proteins, the hydrophobic 
residues buried in the wild type protein remained buried even though the facing residues 
inside the coiled-coil were modified due to the deletions. 
 
Biochemical characterisation of wild type and truncated dystrophin 
To understand how the structure modifications observed on the molecular models could be 
related to the biochemical and biophysical properties of the proteins, they were expressed in 
E. coli (Table 2). All were obtained with degrees of purity close to 95%, as determined by 
SDS-PAGE (Fig. 3A). 
 
Truncated proteins are folded into coiled-coils like wild type dystrophin 
To examine the effect of the deletions on the secondary structure of dystrophin, the wild type 
and truncated dystrophins were analysed using circular dichroism (CD). All of the structures 
had typical CD spectra with two minima at 208 and 222 nm. The values at 222 nm indicated 
alpha-helix contents that ranged between 50 and 75%. Interestingly, the CD spectra showed 
that the ratio of the molar ellipticity at 222 and 208 nm was greater than or equal to 1 for all 
proteins, meaning that all the proteins were folded predominantly into coiled-coils (23)(Fig. 
3B).    
 
The truncated proteins remained highly stable compared to wild type dystrophin 
To determine if the deletions induce modifications in stability, thermal heating was followed 
by CD at 222 nm, and chemical denaturation by urea was followed by tryptophan intrinsic 
fluorescence. Thermal heating and urea denaturation revealed typical sharp two-state 
transitions for all of the proteins. The highest thermal mid-denaturation at 66 ± 0.8°C was 
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recorded for wild type R16-21. Similar values were observed for the truncated proteins R∆45-
47 and R∆45-48 at 65°C, and lower values at 61°C were measured for R∆45-49 and R∆45-51 
(Fig. 3C). The wild type R16-21 protein displayed a mid-denaturation at 5.2 M urea. A similar 
behaviour was observed for the truncated protein R∆45-47, while mid-denaturation was 
achieved with lower urea concentration for the three other proteins (4.9 to 5 M of mid-
denaturation) (Fig. 3D). However, the wild type protein exhibited the highest stability, 
indicating that protein length and the presence of hinge 3 do not preclude stability. We can 
conclude that the two truncated proteins R∆45-47 and R∆45-48 were roughly as stable as wild 
type R16-21, whereas the two shorter truncated proteins showed slightly decreased stability 
compared to the full-length fragment. However, compared to point mutations that modify the 
sequence, these four proteins obtained by joining non-neighbouring regions of the wild type 
protein were highly stable, consistent with previous studies demonstrating that this region of 
the dystrophin central domain is highly stable compared to the more proximal region such as 
this of repeats 1 to 3 (24) and remained highly stable even after the exon coded sequence 
deletions.  
 
Refolding properties after urea denaturation are highly modified in the truncated dystrophin 
fragments compared to the full-length R16-21 protein. 
Refolding after denaturation is a critical dynamic parameter. Refolding after 8 M urea 
denaturation of the full-length and the three truncated proteins R∆45-47, R∆45-49 and R∆45-
51 was described by mono-exponential fits. The fastest mono-exponential refolding rate 
constant at 10.6 ± 2.9 s-1 was observed for the R∆45-51 truncated protein (p<0.0001) (Fig. 
3E). The two other truncated proteins R∆45-47 and R∆45-49 displayed slower refolding rate 
constants of 4.3 and 3.0 s-1, respectively. Interestingly, the refolding of R∆45-48 was better 
described by two exponential components, one corresponding to a fast phase at 12.4 ± 4.4 s-1 
and one to a slower phase at 2.3 ± 0.6 s-1, each of them contributing approximately half of the 
total amplitude. The fast component was similar to the refolding rate constant of the truncated 
protein ∆45-51, and the slow rate constant was the slowest rate reported. The refolding rate 
constant of wild type R16-21 was intermediate at 5.7 ± 0.7 s-1. This value was significantly 
different from all other values, indicating that refolding is not slowed by the length of the 
protein. However, the fastest value was reported for the shorter truncated protein R∆45-51, 
the only fragment lacking hinge 3, indicating that the presence of hinge 3 could slow down 
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the refolding process. Clearly, the two truncated proteins R∆45-47 and R∆45-49 display 
slower global refolding than the other truncated proteins. The refolding rates of the truncated 
proteins were linearly and inversely correlated with the increases in the percentage of the 
hydrophobic surface exposed to solvent (R=0.98, not shown). Indeed, the solvent exposure of 
some hydrophobic residues that were buried in the wild type protein slowed down the 
refolding process. The refolding rates and MD data suggested that hybrid and fractional 
repeats could be distinguished by their dynamic properties. The refolding rates indicated that 
the fractional repeats required additional time to find the correct fold compared to the wild 
type and to hybrid repeat-containing proteins. These observations were in agreement with the 
MD results, which indicated that fractional repeats had topologies and properties far different 
from those of the wild type and hybrid repeat-containing proteins.  
 
Age of DCM onset and of WC dependency of the BMD patients 
From an initial cohort of 251 French patients carrying one of the four studied deletions ∆45-
47 (127 patients), ∆45-48 (90 patients), ∆45-49 (31 patients) and ∆45-51 (3 patients) (Table 
3), we were able to compare the clinical outcome in a subset of 106 patients aged >16 years 
for whom the ages of onset of DCM and/or WC dependency were known: ∆45-47 (n=50), 
∆45-48 (n=38) and ∆45-49 (n=18). Among them, 18 patients exhibited both DCM and WC 
dependency (Supplementary table 1). 
Our data showed a significant difference towards earlier DCM onset in ∆45-47 BMD patients 
(median age of 27 years) compared to ∆45-48 patients (median age of 38 years, p=0.031) or 
∆45-49 BMD patients (median age of 41 years, p=0.042) (Fig. 4A). In addition, we observed 
that WC dependency exhibited a clear trend toward affecting ∆45-48 BMD patients at an 
older age than ∆45-47 BMD patients, with a delay of 11 years (median ages of 49 and 38 
years, respectively), although this difference did not reach statistical significance (p=0.082) 
(Fig 4B). Conversely, ∆45-49 BMD patients became WC confined at a similar median age (35 
years) as ∆45-47 patients (38 years, p=0.416) but 14 years earlier than ∆45-48 patients (49 
years, p=0.029). These differences clearly indicated that the severity spectrum was shifted 
toward slower disease progression for ∆45-48 BMD patients compared to ∆45-47 and ∆45-49 
BMD patients. ∆45-51 patients could not be discussed here as none of the 3 patients in the 
original cohort were WC confined or DCM affected. 
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Dystrophin expression levels in BMD patients 
When available in this retrospective cohort study, dystrophin amounts from Western blots 
(WB) were classified into 4 levels (normal, high, medium and low). Data were available for 
79 of the 239 patients bearing one of the four deletions in the initial cohort and showed that 
most of them displayed a medium level of dystrophin, while the sixth of patients displayed 
low, high or normal levels for each of the deletions (Fig. 4C). When considering only the 
patients with DCM or WC bound, they also displayed mostly medium levels of dystrophin. 
Only four patients with ∆45-47 and one with ∆45-48 had low levels of dystrophin while 7 
patients with ∆45-48 and 3 patients with ∆45-47 had high or normal levels of dystrophin (Fig. 
4D).  
 
Discussion 
By combining several approaches including (i) in-depth structural and biochemical 
investigations of truncated dystrophin molecules and (ii) clinical assessment in large subsets 
of French BMD patients with identical mutations, we provided clues about the role of the 
structure of dystrophin at the deletion site on disease progression in patients carrying in-frame 
deletions in the central rod domain of the protein. Clearly, refolding rates and molecular 
simulations data suggested that hybrid and fractional repeats could be distinguished by their 
dynamic properties. 
The heterogeneity of the BMD phenotype has long been investigated. Whereas in-frame 
deletions in the N-terminal actin-binding domain or in the CYS-rich domain were reported to 
result in a more severe clinical outcome (6, 17), phenotype in patients carrying deletions in 
the central rod domain of dystrophin was more variable, ranging from isolated elevated blood 
creatine phosphokinase and cramps to classical BMD (6, 9, 25). Although the reasons for this 
variability are not fully understood, it is likely that both levels and functionality of the 
internally deleted dystrophins play a significant role (26-28).  
 
Most BMD patients have reduced dystrophin expression levels, the milder phenotypes being 
associated with the higher expression levels (26). Thus, as high as 75% of normal dystrophin 
expression is found in patients with the very mild ∆45-51 deletion (26, 29), and asymptomatic 
patients have significantly higher dystrophin expression levels compared to symptomatic 
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BMD patients (25, 26, 30). In our cohort, the majority of BMD patients were classified as 
having medium level of dystrophin expression. However, dystrophin amounts were 
heterogeneous between patients carrying different deletions but also between patients carrying 
the same deletion as previously shown (6, 8, 25, 26, 29, 31, 32), and did not correlate with the 
age of onset of DCM or of wheelchair dependency. Measuring dystrophin levels accurately 
remains highly challenging (33) and the levels may be variable within a single myofiber, 
between adjacent myofibers and between muscle biopsies. It has also been proposed that at 
expression levels lower to 75% and higher than 30%, the structural characteristics of the 
internally deleted dystrophins could play a significant role in the phenotype (34). This 
assumption was consistent with a recent study showing that there is no linear correlation 
between dystrophin levels and disease severity in BMD patients, notably those carrying a 
∆45-47 deletion: as long as dystrophin level is above a threshold (estimated to be around 
10%), the mutation is likely an important factor in determining disease severity (32). 
Previous studies that aimed to explore the underlying rationale of clinical variability in BMD 
patients were mostly based on the analysis of heterogeneous groups of patients carrying 
different types of deletions even though located in the same gene region: patients with distal 
versus proximal deletions or in the center of the dystrophin central rod domain (6, 8, 25, 31), 
those with deletions ending at specific exons (12, 30) or with deletions including or omitting 
hinge 3 (12, 35). Very often patients were relatively young and still ambulatory, and the 
cardiac status was not reported. Overall, the obtained data suggested that the central region is 
not completely homogenous with respect to function, but did not allow to support a clear view 
of genotype-phenotype correlations in BMD patients having deletions in the central rod 
domain of dystrophin.  
 
The methodology used here to address this question was based on the retrospective analysis of 
large subsets of BMD patients bearing identical deletions for whom two readily comparable 
and robust items as markers of disease severity (age of DCM and WC dependency) could be 
obtained. A comparison analysis was performed between clinical outcome in patients bearing 
∆45-47, ∆45-48, ∆45-49 and ∆45-51 deletions and the predictive functionality of the 
truncated proteins based on the molecular properties of hybrid versus fractional repeats at the 
deletion site compared to wild type. The concept of hybrid repeat is reminiscent of the 
phasing of the repeats in mini- or micro-dystrophins studied by Harper et al. (36). They 
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showed that the mini-dystrophin ∆H2-R19 containing eight perfectly phased repeats 
significantly improved mdx mouse muscle function compared to the closely related construct 
with a deletion of the exons 17 to 48. This deletion was originally observed in a patient (37) 
and contains “non-phased” repeats that give rise to a fractional repeat according to our 
predictions. Specific attention was drawn to repeats phasing in the design of the subsequent 
studies with mini- and micro-dystrophins in mdx mouse or grdm dog (38-40). The most 
popular micro-dystrophin is the ∆R4-R23 / ∆CT which is perfectly phased (41, 42). However, 
the mini-dystrophin ∆H2-R19 was reported to be prone to aggregation in an in vitro assay (43) 
emphasizing the idea that the presence of non-native inter-repeat junction could partly 
compromise the dystrophin function. Quite differently, the presence of hybrid or fractional 
repeats at the deletion site (19, 20) is due to the fact that the B-helices of all the repeats except 
repeat 14 are encoded by two successive in-frame exons, with their boundaries precisely 
aligned with the third heptad of the B-helices (18). Thus, a deletion that maintains the coding 
of a B-helix by two exons around the deletion site allows for the formation of a hybrid repeat 
similar to a true repeat. This type of deletion maintains the heptad pattern of the residues 
along the primary sequence (44) and allows hydrophobic residues to be localized inside the 
coiled-coils which favours a fast refolding. By contrast, in case of a deletion that leads to a 
fractional repeat, hydrophobic residues are not folded inside a coiled-coil but remain 
accessible to the solvent, slowing down the refolding process and constituting sites of 
weakness in dystrophin. Both hybrid and fractional repeats at the deletion sites did not 
decrease dramatically the protein stability indicating that overall the dynamical properties 
were of highest importance for the function of dystrophin. This was not striking since 
dystrophin is primary involved in the resistance to the stress of elongation in muscle cells (45, 
46). However, the deletions that lead to hybrid repeats had the least impact on the structure of 
dystrophin, even if hinge 3 was also deleted. Kaspar et al. (12) anticipated the rule of hybrid 
versus fractional repeats, which they called in-phase and out-of-phase repeats, respectively. 
They suggested that the topology of the truncated protein produced by ∆45-47 reversed the 
direction of the filament. In contrast, here we showed a topology that remained filamentous in 
R∆45-47, even though there was an incomplete coil-coiled structure at the deletion site. 
Indeed, in Kaspar et al. previous study, mutated models were manually constructed 
considering that each repeat contained both a long and a short helix. This was not in line with 
the clear features now available from the X-ray crystals of spectrin and dystrophin repeats, 
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which showed that repeats are made of three helices gently wrapped in a coiled-coil (47). 
Therefore, our data argued for a conserved filamentous structure in R∆45-47 and a profoundly 
modified topology of R∆45-49. Finally, we showed here that it is not the absence of hinge 3 
that correlated with the age of onset of DCM (12) but the structure of these truncated 
dystrophins. 
According to the structural and dynamic modifications observed in the various internally 
truncated mutants studied, we suggested a functional classification such that R16-21 > R∆45-
51 > R∆45-48 > R∆45-47 ~ R∆45-49, that is partly dependent on the presence of hybrid 
versus fractional repeats at the deletion sites. 
 
Is this classification relevant at the biological and clinical levels? 
The analysis of our cohort of patients allowed clear trends for cardiac and/or motor severity to 
be established depending on the truncated protein structure. We showed that severity 
gradation among the four most frequent BMD deletions increases from ∆45-51, through ∆45-
48 and up to ∆45-47 and ∆45-49, with ∆45-48 patients being affected by DCM 11 years later 
than ∆45-47 patients and patients with ∆45-47 and ∆45-49 being at risk to be WC-dependent 
11 to 14 years earlier than patients with ∆45-48. These observations strongly correlated with 
the presence of hybrid repeats at the deletion sites in the R∆45-51 and R∆45-48 truncated 
proteins and with the presence of fractional repeats at the deletion sites of the R∆45-47 and 
R∆45-49 truncated proteins. Because R∆45-51 is the truncated protein the most similar to 
wild type, it is tempting to correlate this similarity with the characterization of ∆45-51 as a 
clinically very mild deletion (48) with a dystrophin expression level of about 75% of wild 
type (26, 29). The lack of symptoms may explain why such a small number of ∆45-51 carriers 
was present in the UMD-DMD database. Although ∆45-48 displayed a hybrid repeat, the 
increased flexibility of this variant compared to the wild type and ∆45-51 proteins could 
partly impair the binding of the actin-binding domain 2 (repeats 11 to 17) to filamentous actin 
(49) thereby explaining why the ∆45-48 phenotype is so different from the very mild 
phenotype of ∆45-51. The ∆45-47 and ∆45-49 deletions lead to fractional repeats at the 
deletion site, which we demonstrated to constitute structurally weakened sites compared to 
hybrid repeats. Whether the dynamic properties associated with the hybrid or fractional 
repeats are relevant in vivo remains speculative, but the folding of this long filamentous 
protein in vivo is probably a rather complex process, and thus deletions that partly impair or 
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slow down this process could be deleterious.  
These results reinforced the idea that the “phasing” of the repeats provides improved function 
to truncated dystrophin (12, 19, 20, 36, 43). This hybrid repeat phasing appears to be essential 
for the function of dystrophin as a molecular shock absorber, protecting the membrane from 
the stresses of contraction (45, 46, 50). In contrast, the fractional repeats are less able to 
protect membrane from the stresses due to their structurally weakened deletion sites. 
Single-exon reported BMD deletions produce fractional repeats (18), although some of them 
have been associated with mild phenotypes, which is not in agreement with the results of this 
study. The structures of such truncated dystrophins remain to be studied in detail, and the 
results could depend on the region of the central domain of dystrophin involved in. Indeed, 
the proximity of a hinge, such as for the deletion of exon 16, or the loss of the binding motif 
for an interacting partner, could also play a role in the severity of the resulting phenotypes 
(51, 52). In that sense, the region covering repeats 16 to 21 was involved in nNOS binding 
(53, 54). For patients with the mild deletion ∆45-55 (55), the mis-localization of nNOS was a 
worsening factor (56) even though this deletion was predicted to lead to a hybrid repeat 
structure of dystrophin.  
This showed that other factors are likely able to modulate the severity of the phenotype 
associated with a deletion leading to a hybrid repeat-containing protein, and may also account 
for the intra and intergroup variability. These factors may include cis-acting elements such as 
spontaneous alternative splicing events occurring in a fraction of dystrophin transcripts (57), 
the presence of non-synonymous SNPs, notably those reported in the exons encoding the 
central rod domain of the protein (58), post-transcriptional regulation by microRNA (59), but 
also other genetic modifiers of disease severity (60-63). 
In conclusion, our findings further support a significant role of the structure of the internally 
truncated dystrophins produced by in-frame deletions in the central rod domain of dystrophin 
in determining disease severity in BMD patients. We showed that the severity of the BMD 
phenotype could be regarded as deletion-specific. Indeed, exon deletions leading to hybrid 
repeats should lead to more favorable clinical outcomes than deletions leading to fractional 
repeats. This primary factor could be further modulated by the presence or absence of a 
binding partner, the presence of specific SNPs that may slightly alter the function of the 
dystrophin protein or by factors modulating the expression such as microRNA or by SNPs. 
From a pragmatic point of view, our study should help caregivers to anticipate the clinical 
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disease course in a patient carrying a given deletion based on the structure of the resulting 
truncated dystrophin. Exon skipping is a promising therapy that aims to convert the severe 
DMD into the milder BMD phenotype by skipping one or several exons in order to restore the 
reading–frame (27, 64-66). Our work indicates that exon skipping will not produce a normal 
dystrophin and that some isoforms generated by this approach will be more functional than 
others. Indeed, restoring the reading-frame would not stabilize but rather slow down disease 
progression depending on the induced in-frame deletion. A better knowledge of the 
functionality of the different isoforms of dystrophin is thus of critical importance for 
predicting the extent of functional benefit that any given patient may have from the exon 
skipping strategy. It is worth mentioning that exon skipping aiming at generating a deletion of 
exons 45 to 51 could be also highly valuable for the most severe BMD deletions. Overall, 
preservation of repeat phasing is a critical determinant of functional outcome of newly 
synthetized proteins in patients that should be considered in various therapeutic approaches, in 
particular micro- or mini-dystrophin gene transfer strategies (27).  
 
 
Materials, Methods and Patients 
In silico analysis 
Molecular homology modelling was used to generate models of the four truncated dystrophins 
to compare them to the wild type R16-21 fragment previously obtained (67). For each 
truncated dystrophin, previously described models were used (18) and were lengthened by 
native repeats added at the C-terminal end (16).  
Molecular dynamics was essentially performed similarly to our previous work (16). To 
simulate our systems with water and ions, we used the program NAMD 2.8 (68) and the 
CHARMM27 force field (69, 70], 71, 72). The initial models were oriented along the z axis 
and then solvated in rectangular water boxes generated using the Solvate plugin of VMD (73). 
We thus ensured that there was a 25Å thick layer of TIP3P water in the x directions and a 35Å 
thick layer in the y and z direction. Subsequently, the VMD plug-in Autoionize was used to 
place ions randomly to neutralize the system. To adjust the position of the solvent (water and 
ions) around the molecules, each system was energy minimized for 10000 steps using the 
conjugate gradient method while restraining the solute atoms with a 25 kcal mol−1 Å−2 
harmonic restraint. 
 Page 15 
 
The entire system (solvent and solute) was then subjected to another 10000 steps of energy 
minimization to relieve any major stresses, followed by a slow heating to 310 K at constant 
volume over a period of 50 ps. The equilibration and production phases were performed for 
40 ns for R16-21, 35 ns for ∆45-48 and 30 ns for the three other molecules applying periodic 
boundary conditions and using a 2 fs time step and the SHAKE algorithm. Van der Waals 
interactions were computed using a cut-off distance of 12 Å with a switching function starting 
at 10 Å, while long-range electrostatic forces were calculated using the particle−mesh Ewald 
method with a grid density of 1 Å-3. To further reduce the cost of computing full 
electrostatics, a multiple-time-stepping procedure was employed to calculate long-range 
electrostatics every 4 fs. Berendsen baths were used to maintain the system temperature and 
pressure at 310K and 1 atm, respectively.  
The Root Mean Square Deviation (RMSD in nm) compares the mean positions of the α-
carbon atoms (Cα) of the peptide bond formed between the α-carboxyl group of one residue 
and the α-amino group of the next one in the protein (74). RMSD is used to measure the 
spatial deviation of all the Cα of the protein model during the time course of the molecular 
dynamic compared to the initial model. It was calculated to determine the equilibration phase 
(i.e. when the RMSD becomes constant signifying that the model no more changes) and the 
last 22ns of trajectories were kept for the analysis of all simulations (Fig. 1S). The Root mean 
square fluctuation (RMSF in nm) reports the mean fluctuation of the position of each Cα 
during the molecular dynamics trajectory. This indicates the sites which are highly dynamical 
(high RMSF) compared to sites which are rigid (low RMSF) (Fig. 2S). To extract 
representative structures, the coordinate frames from the trajectory were clustered using the 
K-means algorithm. After testing different values, we chose to split the trajectory into three 
clusters (74). Molecular hydrophobicity potentials (MHP) were computed by the Platinum 
server (75, 76) using the Ghose forcefield parameters. Electrostatic potentials were computed 
with the program APBS (68) using the Charmm forcefield and 50 mM concentrations for both 
sodium and chloride ions. 
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Biochemical analysis 
Materials 
The pGEX-4T1 plasmid vector, GSTrapTM HP column were purchased from GE Healthcare. 
The E.coli BL21(DE3) bacteria were supplied by Invitrogen and restriction enzymes by New 
England Biolabs. 
Cloning, expression and purification of proteins 
The plasmid pTG11025 harbouring the cDNA for the Dp427m muscle isoform of human 
dystrophin (NCBI Nucleotide Data Base NM-004006, provided by S. Braun Transgene, 
France) was used as a template for PCR amplification of fragments. The four truncated 
dystrophins resulting from deletions of exons 45-47, 45-48, 45-49 and 45-51 were introduced 
into a fragment of dystrophin recovering repeats R16-21 (Table 1). This choice was guided by 
the desire to maintain the same N- and C-terminal ends for all of the deletions and an entire 
repeat at each end, i.e., repeat 16 at the N-terminal end and repeat 21 at the C-terminal end, 
even in the presence of internal deletions. The presence of the N- and C-terminal ends would 
be indispensable for maintaining the true folding of the fragment (77). The construct was 
generated by PCR and cloned into pGEX-4T-1 vector using BamHI and XhoI restriction sites 
as previously described (24, 67). For exon-deleted constructs, the exon 48 / repeat 21 
fragment to exon 52 / repeat 21 fragment was generated by PCR amplification with an “exon” 
primer including a BspTI restriction cassette at the 5’ end and R21 primer (see Table 1S for 
the primers). Products were cloned into the wild-type construct using BspTI (end of exon 44) 
and XhoI restriction sites, resulting in exon deletion. All the constructs were checked by a Big 
Dye terminator sequencing procedure. Recombinant proteins were expressed as GST tagged 
proteins in the protease-deficient E. coli BL-21 strain. Cultures were performed at 37°C in LB 
medium supplemented with 50 µg/ml of ampicillin. The protein expression was induced by 
0.5 mM IPTG addition for four hours. Cells were harvested by centrifugation at 2500g for 20 
minutes. 
The wild type R16-21 was expressed as a soluble protein, whereas all truncated proteins were 
produced as inclusion bodies. All proteins were finally obtained as soluble forms after 
solubilization with n-lauryl-sarcosine (0.1%), affinity chromatography and further purification 
either with hydrophobic chromatography (R∆45-47 and R∆45-48) or not (R∆45-49 and 
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R∆45-51). Exclusion chromatography performed at the end of the purification process 
showed that the proteins were all monomeric. Proteins were concentrated in a Tris 20mM pH 
7.5 buffer containing NaCl 150 mM, EDTA 0.1 mM and glycerol 5% (TNEG buffer) using 
centrifugation-based concentrators and concentration was determined by spectroscopy at 280 
nm and using theoretical molar extinction coefficients.  
 
Circular dichroism and fluorescence analysis of the purified proteins 
Circular dichroism was performed with a JASCO J-810 (Nantes, France) spectropolarimeter 
with protein concentration of about 2.5 µM against the TNEG buffer. Spectra were acquired 
in the range 200 – 250 nm at 20°C with a path length of 0.2 cm. The percentage of α-helix 
was obtained using a 100% α-helix value of -36000 deg .cm2.dmol-1 at 222 nm as previously 
described (78). Thermal unfolding was followed at 222 nm with temperature increase of 
1 deg/min from 15 to 85°C. As partial refolding after heating at 70°C was observed showing 
that denaturation was reversible, CD signal was fitted to a two-state transition as previously 
described (78).  
Tryptophan fluorescence spectra of the five proteins at 0.5µM in TNE buffer were recorded 
on a Fluorolog spectrofluorimeter (Horiba Jobin-Yvon, Longjumeau, France) at 295 nm 
excitation wavelength at 20°C. After appropriate buffer correction, emission spectra of non-
denatured proteins were obtained. Urea unfolding was performed by incubating proteins with 
urea from 0.5 to 8M in TNEG buffer with 0.1 M steps for two hours before fluorescence 
measurement. The maximum wavelength (λmax) and the intensity of fluorescence were 
measured from the emission spectra. Reversibility of the denaturation was checked by ten-
fold dilution of the 8 M urea-treated protein and by observing similar spectra of this diluted 
and native protein. The analysis of the denaturation was analysed as previously described 
(24).  
Stopped-flow data were recorded on a stopped-flow BioLogic SFM-3, MOS 250 (Grenoble, 
France) device with a dead time of 2.2 ms. Proteins were diluted in 8M urea two hours before 
refolding measurements. As a first control, the urea denatured proteins were diluted ten-fold 
in TNE and their tryptophan fluorescence recorded. Each protein was able to refold with the 
same tryptophan fluorescence spectrum after renaturation and therefore, the refolding after 
8M urea denaturation could be used to follow the refolding by stopped flow fluorescence. The 
refolding reactions were initiated at 20°C by tenfold dilution of the urea-treated proteins in 
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TNEG buffer giving final protein concentrations of 0.25 µM. The time-dependent of 
tryptophan fluorescence changes were monitored at excitation and emission wavelengths of 
295 nm and 345 nm, respectively. Curves were derived from the averages of at least ten 
individual kinetic data points after subtraction of the background urea buffer signal. The 
refolding rate constants were obtained by fitting the data with mono- or bi-exponential 
functions.  
 
BMD patient cohort  
This is a retrospective study using the national UMD-DMD France database (17) which 
collected data of DMD and BMD patients identified since more than 20 years. Two-hundred 
fifty-one BMD patients carrying one of the four in-frame deletions (∆45-47, ∆45-48, ∆45-49 
or ∆45-51) were retrieved from the database (Table 3). Only the patients older than 16 were 
further considered for the study. The comparison of disease severity between the four groups 
was based on two clinical criteria: the age of dilated cardiomyopathy (DCM) onset (defined as 
the age when a left ventricular ejection fraction value ≤55% as determined by 
echocardiography was observed) and the age at permanent WC use. To avoid bias in our 
analysis, we did not include patients with non-permanent WC due to the difficulty in 
quantifying this criterion (duration of WC use, use inside or outside the home, maximal 
walking distance) from one patient to another. Overall, 106 patients had definite DCM and/or 
were WC users with the deletions ∆45-47, ∆45-48, ∆45-49, 19 of which displayed both DCM 
and WC use (Table 2S). No patient with DCM or WC dependency was found in the subgroup 
of 3 BMD patients with ∆45-51. Furthermore, we collected data of dystrophin WB analysis 
using DYS1, DYS2 and DYS3 antibodies (79) performed during the diagnostic approach for 
47 over the 106 patients. A semi-quantitative evaluation by visual inspection of dystrophin 
expression level was done. For each patient, dystrophin amounts were compared to control 
muscle extracts in three conditions, no dilution and ½ and 1/3 dilutions. The levels were then 
visually categorized into four amount classes: normal (~70-100% of control), high (~50-70% 
of control), medium (~10-50% of control) and low (< 10% of control) (Table 2S).  
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Figures 
 
Figure 1. Structural consequences of the exon deletions obtained by in silico molecular 
homology modelling  
Schematic representation of the exons and their corresponding encoded proteins of interest, with their 
molecular weight. On the top of each drawing, the exons are noted by their numbering: a vertical bar 
indicates an “in-frame” succession of repeats while the > sign indicates an “out-of-frame” succession 
of exons. The new bounded exons around a deletion are indicated in red. Repeats are coloured and 
numbered according to the alignment from Winder (44). The green diamond represents the hinge 3. 
Molecular homology models are shown on the right of the schematic representation of proteins (cyan: 
R16, purple: R17, yellow: R18, grey: R19, red: R20, orange: R21). An inset shows that a tandem 
repeat is made of three helices, A, B and C, joined by loops and structured in a coiled-coil; the 
continuity of the filament is obtained by the common helix containing the C-helix of the first repeat 
followed by the A’-helix of the following repeat. In the R16-21 model, each wild-type repeat has three 
alpha-helices gently wrapped in a coiled-coil. This filamentous structure is interrupted by the presence 
of hinge 3 in green. Models of the four truncated proteins are presented with the repeats coloured as in 
the wild type R16-21. The truncated proteins all bear deletions starting at exon 45, which encodes the 
C-terminal half of repeat 17. The R∆45-47 protein lacks part of repeats 17 and 18 and forms a 
structure clearly different from a true repeat at the site of the deletion. This incomplete repeat is known 
as a “fractional repeat”. R∆45-48 is lacking part of repeat 17, all of repeat 18 and part of repeat 19 and 
a structure similar to a true repeat is formed at the site of the deletion, with three helices forming a new 
coiled-coil called “hybrid repeat”. R∆45-49 is truncated from the middle of repeat 17 to the middle of 
repeat 19, and the two remaining parts of repeats 17 and 19 form two helices wrapped in a double 
coiled-coil; as the third helix of a conventional repeat is lacking in this mutant, the directionality of the 
molecule at the junction with hinge 3 is changed. This mutant therefore bears a “fractional repeat” 
with a non-filamentous topology. R∆45-51 lacks part of repeat 17 and all of repeats 18 and 19 and 
hinge 3; the remaining parts of repeat 17 and of repeat 20 make a “hybrid repeat”.   
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Figure 2. Analysis of the molecular dynamics relaxation of the five homology models 
After 22 ns of molecular relaxation, the most representative model of each protein is showed (colour 
code similar to Fig. 2). Specific points of flexibility are indicated (arrows). The wild type R16-21 
shows a point of flexibility at the R18-19 linker, whereas R∆45-47 and R∆45-49, structured in 
fractional repeats, shows high flexibility at their respective deletion sites. The two hybrid repeats of 
R∆45-48 and R∆45-51 maintain their initial structures, with the R∆45-48 tending to fluctuate at the 
region linking repeat 19 to hinge 3. (B) Electrostatic potential projected on the solvent-accessible 
surface of the wild type and the truncated dystrophins. Each model was coloured using the APBS 
electrostatic potential calculated for an ionic strength of 50 mM and the surface colours were clamped 
at -3 (red) and +3 (blue) kTe-1. Only the regions around the deletion site and corresponding to repeat 
16-17 (R16-17) of the wild type are shown. (C) Isoelectric points were calculated using primary 
sequences. (D) Molecular hydrophobicity potentials were obtained from PLATINUM server and 
displayed using VMD. The hydrophobicity scale is green-white-yellow, with green representing the 
most hydrophilic regions and yellow the most hydrophobic. Only the regions focused in (B) are 
shown. (E) Mean solvent exposed hydrophobic surface ± SD of the three clusters obtained by 
molecular dynamics (% of the total surface). *, # the values are identical from each other and different 
from the other (p<0.05); ** the value is different from all other values (p<0.05).  
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Figure 3. Biochemical consequences of the exon deletions compared to wild type  
Proteins were expressed in E. coli and further purified by affinity chromatography. (A) SDS-
PAGE of the five proteins revealed by Coomassie blue staining. Molecular weight markers are 
on the left side of the gels. Protein purity is over 95%. (B) CD spectroscopy performed with 
wild type R16-21 and the four truncated proteins. The spectra of the molar ellipticity vs 
wavelength showed two minima at 208 and 222 nm, as expected for proteins folded in alpha-
helices. (C) The temperature at mid-denaturation and (D) urea at mid-denaturation are plotted. 
Values are reported as the mean ± SD of at least three measures. *Values similar and different 
from all other values (t-test, p<0.05). (E) Refolding rate constants were measured by stopped-
flow fluorescence. Proteins unfolded in 8M urea were tenfold diluted in urea-free buffer and 
intrinsic tryptophan fluorescence was monitored. Values represent exponential rate constant ± 
SD for at least five experiments. #Values significantly different from all other values (t-test, 
p<0.05); **Values identical and significantly different from all other values (p=0.0001) 
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Figure 4. Ages of DCM onset and WC dependency and dystrophin expression levels 
from the ∆45-47, ∆45-48, ∆45-49 and ∆45-51BMD patients  
Dots indicate the individual age of DCM onset or WC dependency, and boxes indicate the location of 
50% of the individual values. Horizontal bars indicate the median age in years. Colored / wide dots 
indicated the dystrophin expression level class of each patient as shown in the inset. (A) Box plot and 
dot plot distributions of age of DCM onset versus deletion type. Analysis of variance (ANOVA) 
revealed a statistically significant difference between groups (p=0.036). The Mann-Whitney test 
revealed a significant difference in the median ages of DCM onset in ∆45-48 and the ∆45-49 BMD 
patients which were 11 years (p=0.031) and 14 years (p=0.042) later, respectively, than the median 
age of DCM onset in ∆45-47 BMD patients. (B) Box plot and dot plot distributions of age of WC 
dependency. ANOVA showed a non-significant p value of 0.088. However, the median age of WC 
dependency was 14 years later in ∆45-48 patients than ∆45-49 BMD patients (p=0.029 by the Mann-
Whitney test). Although the difference was not statistically significant (p=0.082 by the Mann-Whitney 
test). WC dependency tended to occur at an earlier age in ∆45-47 patients (median age, 38 years) 
compared to ∆45-48 patients (median age, 49 years). (C) and (D) Dystrophin amounts are reported 
after semi-quantitative inspection of WB. By comparison with control normal muscle extracts, the 
levels were categorized into four classes: normal (~70-100% of control amount), high (~50-70% of 
control amount), medium (~10-50% of control amount) and low (< 10% of control amount) (see also 
Table 2S). The numbers of patients per class and per deletion type were reported. (C) Dystrophin 
amounts for all the BMD patients of the cohort whatever the cardiac and muscle status. (D) 
Dystrophin amounts for the patients of A and B. 
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Table 1. Distribution of the residues (%) in the dihedral Ψ/Φ angles values of the 
Ramachandran plot regions  
 
Proteins Models 
Energetically 
favoured 
region* 
Energetically 
moderately 
favoured 
region** 
Energetically 
unfavoured 
region*** 
Initial model 98 0.8 1.2 R16-21 
 
After  MD 98.6 1.4 0.0 
Initial model 97 1.0 2.0 R∆45-47 
 
After  MD 98.2 1.4 0.4 
Initial model 97.1 1.6 1.3 R∆45-48 
 
After  MD 98.7 1.3 0.0 
Initial model 96.9 1.4 1.7 R∆45-49  
 
After  MD 99.1 0.5 0.5 
Initial model 97.8 0.6 1.6 R∆45-51 
 
After  MD 99.1 1.0 0.6 
*, **, ***corresponding to the classical Ramachandran core and allowed*, generously 
allowed** and disallowed *** regions. 
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Table 2. Sequence and molecular weight of the wild type R16-21 and the four truncated 
proteins 
 
 
Protein 
(number of 
residues) 
First  
residue 
Last 
residue 
N-terminus 
sequence 
C-terminus 
sequence 
Molecular 
weight 
(kDa) 
R16-21 wild 
type (706) 
1991 2694 LEISYV… …ETHRLLQQF 82 
 
 
Protein 
(number of 
residues) 
Residue in N-
terminal of the 
deletion  
Residue in C-
terminal of the 
deletion  
Sequence of the 
junction of the 
deletion 
Molecular 
weight (kDa) 
R∆45-47 
(548) 
2146 2305 …WYLKVSRA… 63.9 
R∆45-48 
(486) 
2146 2365 …WYLKETEI… 56.7 
R∆45-49 
(452) 
2146 2401 …WYLKRKLE… 52.9 
R∆45-51 
(338) 
2146 2515 …WYLKATMQ… 40.1 
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Table 3. Description of the French BMD patients’ cohort 
 
 
Deletions 
(number 
of 
patients) 
Mean age 
in years 
(age 
range) 
Number of patients with 
DCM or not  
(% of the number of 
patients)  
(number of patients with 
known age of onset) 
Number of patients using 
wheelchair or not 
(% of the number of patients) 
(number of patients with known 
age of onset) 
 
Patients 
with both 
DCM and 
WC 
permanent 
use 
(% of the 
number of 
patients) 
 
  Yes No Unkno
wn 
Alway
s 
Parti
al 
None Unkno
wn 
 
∆45-47 
(127) 
46  
(17-79) 
40 
(32%) 
(35) 
58 
(47%) 
27 
(21%) 
 
23 
(18%)
(18) 
15 
(13%
) 
85 
(67%) 
2 
(2%) 
6 (5%) 
∆45-48 
(90) 
47  
(18-83) 
34 
(38%)
(31) 
38 
(42%) 
18 
(20%) 
15 
(17%)
(12) 
8 
(9%) 
65 
(72%) 
2 
(2%) 
5  
(6%) 
∆45-49 
(31) 
49  
(20-80) 
17 
(55%)
(14) 
9 
(29%) 
5 
(16%) 
14 
(45%)
(11) 
5 
(16%
) 
11 
(36%) 
1 
(3%) 
7  
(23%) 
∆45-51 
(3) 
25  
(20-31) 
0 2 1 
 
0 1 2 0 0 
Partial wheelchair use includes patients who are still ambulant but are using a wheelchair for 
long distances or only outdoors. The “Unknown” status corresponds to those patients for 
whom no recently updated neurologic or cardiologic data are available. 
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Abbreviations 
DMD = Duchenne muscular dystrophy; BMD = Becker muscular dystrophy; DCM = dilated 
cardiomyopathy; WC = wheelchair; MD = molecular dynamics; CD = circular dichroism; 
nNOS = neuronal nitrous oxide synthase; EDTA = ethylene diamine tetra-acetic acid. 
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Becker Muscular Dystrophy severity is linked to the structure of dystrophin 
Nicolas et al. 
 
Supplementary Figures and Tables 
 
 
Fig. 1S. Cα Root Mean Square Deviation between the initial model and the snapshots of the 
five proteins taken every picosecond (ps) during the 30-40 nanoseconds (ns) of the molecular 
dynamic trajectory. For all simulations, the production period is 22 ns equally long. 
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Fig. 2S. Root Mean Square Fluctuation of the Cα for the five proteins calculated over the 
production period of each molecular dynamics simulations. Profiles clearly indicate that 
secondary structure elements (alpha-helices) are well maintained – showing less fluctuations – 
along the period selected for analysis. 
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Fig. 3S. The conformational states recorded along molecular dynamics trajectories were 
clustered into three representative structures (C0, C1 and C2). The percentage of cluster 
representativeness over the whole trajectory is indicated. 
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Table 1S: Primers sequence list 
Primer Name Primer sequence  5’-> 3’ 
R16-lg BamHI F aaccatatgggatccTTGGAAATTTCTTATGT 
R21-lg StopXhoI R atcctcgagttaGAACTGTTGCAGTAATCTATGAGTTTC 
Exon47_ BspTI F caccttaagTTACTGGTGGAAGAGTTGC 
Exon48_ BspTI F caccttaagGTTTCCAGAGCTTTACCTGAGAA 
Exon49_ BspTI F caccttaagGAAACTGAAATAGCAGTTCAAGC 
Exon50_ BspTI F caccttaagAGGAAGTTAGAAGATCTGAGCT 
Exon52_ BspTI F catcttaagGCAACAATGCAGGATTTGG 
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 Table 2S. Detailed clinical and western blot data of the 106 BMD patients that had definite 
DCM and/or were WC users.  
 
∆45-47 
DCM  Patient 
 
Age at last 
follow-up 
age of DCM 
onset 
LVEF 
(%) 
Age at 
full time 
WC use 
Dystrophin 
level as 
quantified 
by WB* 
Dystrophin 
size as 
assessed by 
WB 
1 68.44 no UK 50 UK UK 
2 54 no UK 54 UK UK 
3 27 27 52 no UK UK 
4 30 21 UK no UK UK 
5 63.61 52 UK no UK UK 
6 25.05 17 UK no low reduced 
7 20.85 19.5 52 no medium reduced 
8 38.12 20.54 50 no medium reduced 
9 29 17 UK no medium reduced 
10 49.08 48.7 53 no medium reduced 
11 25.3 20.27 50 no medium reduced 
12 39 29 UK no high reduced 
13 46.24 42 41 no UK UK 
14 36 26 UK no medium reduced 
15 30 29.03 UK no UK UK 
16 34 23 51 no medium reduced 
17 38.29 17.41 50 no UK UK 
18 20.45 15.62 UK no UK UK 
19 20.1 20.09 50 no UK UK 
20 30.52 27.58 45 no UK UK 
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21 22.93 17 48 no UK UK 
22 41.22 26.41 41 no UK UK 
23 45.27 36.77 44 no normal reduced 
24 13.56 12.62 UK no low normal 
25 52 UK UK 15 UK UK 
26 16 no UK 16 UK UK 
27 25.85 no UK 25.85 medium reduced 
28 53.67 40.13 UK 30 UK UK 
29 45.16 no UK 31 medium reduced 
30 44.04 no UK 31 UK UK 
31 44.16 30 50 31 UK UK 
32 53.23 49 52 34 UK UK 
33 43.79 no UK 36.99 UK UK 
34 43.98 no UK 38 low reduced 
35 47.67 43.16 UK 39.16 UK UK 
36 60.53 UK UK 40 UK UK 
37 44.56 no UK 44.56 UK UK 
38 53 46 35 50 normal reduced 
39 55.61 no UK 55 low normal 
40 67.38 UK UK 65.45 UK UK 
41 57.17 54.79 32 no UK UK 
42 49.26 39.29 24 no UK UK 
43 48 43 UK no UK UK 
44 55.45 47 40 no UK UK 
45 36 27 UK no UK UK 
46 50.97 37.4 35 18 UK UK 
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47 57.22 no UK 50 medium reduced 
48 56.4 no UK 54.67 medium reduced 
49 32.01 17.84 40 no UK UK 
50 60.21 56.86 32 no UK UK 
 
∆45-48 
DCM  Patient Age at last 
follow-up 
Age of DCM 
onset 
LVEF 
(%) 
Age of 
full 
time 
WC use 
Dystrophin 
level as 
quantified by 
WB* 
Dystrophin 
size by WB 
1 53.64 52.2 40 47.78 UK UK 
2 74.38 UK UK 50 UK UK 
3 46.59 UK UK 35 UK UK 
4 52 no UK 45 normal reduced 
5 43 UK UK 40 UK UK 
6 47 36 54 41 medium reduced 
7 51.06 51.06 UK 50.79 medium reduced 
8 61.74 49.91 55 51.47 UK UK 
9 64.28 60 52 54.62 medium reduced 
10 55.66 42 UK no UK UK 
11 61.17 59 UK no normal reduced 
12 66.44 65 UK no UK UK 
13 17.11 17 55 no high reduced 
14 18.45 17.12 52 no medium reduced 
15 20.25 19.75 UK no medium reduced 
16 33.65 19.95 53 no medium reduced 
17 24.29 22 50 no UK UK 
18 32.68 27.77 UK no UK UK 
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19 29.62 29.54 22 no medium reduced 
20 35.27 31 31 no high reduced 
21 33.4 31.3 48 no UK UK 
22 42.7 34 55 No high reduced 
23 38.26 35 53 no UK UK 
24 42.45 35 UK no normal reduced 
25 41.3 41.3 UK no UK UK 
26 41.23 42 UK no medium reduced 
27 52.3 42.67 UK no UK UK 
28 44.45 44.04 35 no medium reduced 
29 61.63 45.5 29 no medium reduced 
30 52.69 51.64 50 no medium reduced 
31 50.43 UK UK 26.45 UK UK 
32 57.29 no UK 54.41 medium reduced 
33 57.12 55.29 35 no normal reduced 
34 49.29 43.9 37 no medium reduced 
35 51.93 38.15 UK no medium reduced 
36 42.72 26.63 UK UK UK UK 
37 24.47 17.97 45 no UK UK 
38 65.57 no UK 65.01 low reduced 
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∆45-49 
DCM Patient 
 
Age at last 
follow-up 
age of 
DCM 
onset 
LVEF 
(%) 
Age at 
full time 
WC use 
Dystrophin 
level as 
quantified by 
WB* 
Dystrophin size 
by WB 
1 55.3 41.58 45 47.04 normal reduced 
2 50.32 45 25 15 UK UK 
3 43.92 42 45 15 UK UK 
4 44.97 44.55 52 29.28 UK UK 
5 41.21 38.1 47 38.55 UK UK 
6 47.87 43.08 46 no UK UK 
7 63.53 63.53 UK 43.94 UK UK 
8 73.42 64.44 UK 69.14 medium reduced 
9 50.13 50 UK UK medium reduced 
10 23.37 18.97 UK no UK UK 
11 32.82 26.21 53 no medium reduced 
12 29.84 27 44 no medium reduced 
13 44 41.87 25 no medium reduced 
14 49.27 no UK 15.5 UK UK 
15 33.45 UK UK 20 UK UK 
16 49.72 UK UK 35 UK UK 
17 53.16 UK UK 45 UK UK 
18 26.86 22 34 no medium reduced 
*For each patient, dystrophin levels as determined by western blot were categorized into four 
visual classes: normal (~70-100% of control amount), high (~50-70% of control amount), 
medium (~10-50% of control amount) and low (< 10% of control amount) by comparison 
with normal muscle extract. 
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LVEF: Left ventricular ejection fraction; UK : unknown ; when UK appears in the “age of DCM 
onset” or “LVEF” columns, this means that the patient had a proven DCM but either the precise age of  
DCM onset or the LVEF value at onset are not available in the medical reports; when UK appears in 
the “age of WC use” column, this means that the patient is a permanently WC user but the precise age 
of full-time WC dependency could not be retrieved from the medical files; “No”, means the absence of 
one of the clinical criteria (DCM or WC dependency) at the last follow-up. 
 
